SCHEMBL1474579

SCHEMBL1474579

COC(OC)c1ccnc(N)n1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.42
KMT2A Q03164 4/20 0.41
MAPT P10636 2/20 0.41
NUDT1 P36639 3/20 0.41
RAB9A P51151 1/20 0.40
ROCK1 Q13464 3/20 0.40
HRH4 Q9H3N8 2/20 0.37
AURKA O14965 1/20 0.37
HSP90AA1 P07900 1/20 0.37
PRKACA P17612 1/20 0.37
ADORA2A P29274 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
CDK4 P11802 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propane SCHEMBL20550793 0.94 POLB (0.47) POLBSMN1; SMN2L3MBTL1KMT2AMAPT
SCHEMBL8479931 0.88 POLB (0.43) POLBSMN1; SMN2L3MBTL1KMT2AMAPT
SCHEMBL12277549 0.82 POLB (0.63) POLBNUDT1ROCK1HRH4AURKA
SCHEMBL11853970 0.79 POLB (0.47) POLBNUDT1RAB9AROCK1HRH4
SCHEMBL2751610 0.78 SMN1; SMN2 (0.46) POLBSMN1; SMN2L3MBTL1KMT2AMAPT
SCHEMBL83993 0.77 POLB (0.56) POLBNUDT1ROCK1HRH4AURKA
SCHEMBL29718738 0.77 POLB (0.56) POLBNUDT1ROCK1HRH4AURKA
SCHEMBL14215338 0.76 SMN1; SMN2 (0.49) POLBSMN1; SMN2L3MBTL1KMT2AMAPT
SCHEMBL4978265 0.76 SMN1; SMN2 (0.45) POLBSMN1; SMN2L3MBTL1KMT2AMAPT
SCHEMBL3275866 0.76 SMN1; SMN2 (0.45) POLBSMN1; SMN2L3MBTL1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108033916-B Preparation of amino acid ester compound and application of amino acid ester compound in preventing and treating tobacco diseases 贵州理工学院 2021-02-26 CN claimed
CN-102675219-A Preparation method of 5-bromo-2-amino-4-dimethoxymethylpyrimidine CGENE TECH SUZHOU CHINA CO LTD 2012-09-19 CN claimed
EP-3619204-B1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2025-10-01 EP disclosed
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2022-12-01 US disclosed
CN-108349896-B Heterocyclic compounds as FGFR inhibitors 南京天印健华医药科技有限公司 2021-06-01 CN disclosed
CN-108033916-B Preparation of amino acid ester compound and application of amino acid ester compound in preventing and treating tobacco diseases 贵州理工学院 2021-02-26 CN disclosed
CN-108033916-B Preparation of amino acid ester compound and application of amino acid ester compound in preventing and treating tobacco diseases 贵州理工学院 2021-02-26 CN disclosed
US-10590109-B2 Heterocyclic compounds used as FGFR inhibitors NANJING INNOCARE PHARMA TECH CO., LTD. (CN) 2020-03-17 US disclosed
US-10590109-B2 Heterocyclic compounds used as FGFR inhibitors NANJING INNOCARE PHARMA TECH CO., LTD. (CN) 2020-03-17 US disclosed
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES THE UNIVERSITY OF MELBOURNE (AU) 2020-03-12 US disclosed
EP-3619204-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES The University of Melbourne (AU) 2020-03-11 EP disclosed
US-5658903-A Imidazole compounds, compositions and use SMITHKLINE BEECHAM CORPORATION (US) 1997-08-19 US disclosed
EP-0727998-A4 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1997-03-19 EP disclosed
US-5593992-A CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-01-14 US disclosed
US-5593991-A ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR SMITHKLINE BEECHAM CORPORATION 1997-01-14 US disclosed
WO-1996040143-A1 IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-12-19 WO disclosed
EP-0727998-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-28 EP disclosed
WO-1996021452-A1 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORPORATION (US) 1996-07-18 WO disclosed
WO-1996021654-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-07-18 WO disclosed
WO-1995013067-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590109-B2 Heterocyclic compounds used as FGFR inhibitors FGFR1, FGFR3, FGFR2 POLB 3498/4885SMN1; SMN2 2539/4885L3MBTL1 4492/4885
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R POLB 1332/4885SMN1; SMN2 3328/4885L3MBTL1 4117/4885
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R POLB 1332/4885SMN1; SMN2 3328/4885L3MBTL1 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.